Personalis (NASDAQ:PSNL) Trading Up 14.8% – Should You Buy?

Personalis, Inc. (NASDAQ:PSNL) shot up 14.8% during mid-day trading on Thursday . The stock traded as high as $11.00 and last traded at $11.0750. 413,681 shares were traded during mid-day trading, a decline of 69% from the average session volume of 1,327,764 shares. The stock had previously closed at $9.65.

Wall Street Analyst Weigh In

PSNL has been the topic of a number of research reports. Lake Street Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Personalis in a research note on Wednesday, November 5th. BTIG Research reiterated a “buy” rating and set a $12.00 target price on shares of Personalis in a research report on Friday, January 9th. Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Morgan Stanley boosted their target price on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Finally, Needham & Company LLC lifted their price objective on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Personalis has a consensus rating of “Moderate Buy” and an average price target of $10.57.

Personalis Stock Performance

The firm’s 50 day moving average is $9.06 and its 200-day moving average is $7.46. The company has a market cap of $903.14 million, a PE ratio of -11.56 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The business had revenue of $14.50 million during the quarter, compared to analyst estimates of $13.31 million. On average, analysts predict that Personalis, Inc. will post -1.4 EPS for the current year.

Insider Buying and Selling at Personalis

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the transaction, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at $1,334,889.14. The trade was a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the completion of the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at approximately $1,772,857.24. This trade represents a 38.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 134,481 shares of company stock worth $1,397,564. Insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its stake in Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after acquiring an additional 802,268 shares during the last quarter. AIGH Capital Management LLC boosted its stake in Personalis by 4.5% during the third quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock worth $25,376,000 after buying an additional 168,143 shares during the period. Aberdeen Group plc increased its position in shares of Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after acquiring an additional 861,948 shares during the last quarter. Kennedy Capital Management LLC raised its stake in shares of Personalis by 196.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares during the period. Finally, Blue Water Life Science Advisors LP lifted its holdings in shares of Personalis by 42.6% in the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after acquiring an additional 500,900 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.